Stephens Inc. AR Lowers Holdings in Eli Lilly and Company $LLY

Stephens Inc. AR cut its holdings in Eli Lilly and Company (NYSE:LLY) by 1.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 36,913 shares of the company’s stock after selling 486 shares during the period. Stephens Inc. AR’s holdings in Eli Lilly and Company were worth $34,130,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $12,976,634,000. Capital Research Global Investors raised its stake in Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP raised its stake in Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. boosted its stake in shares of Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after acquiring an additional 1,432,069 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on LLY shares. Jefferies Financial Group upped their price objective on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 2nd. Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research report on Monday. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, Guggenheim restated a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,243.22.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $35.65 during mid-day trading on Tuesday, hitting $1,235.71. The stock had a trading volume of 904,272 shares, compared to its average volume of 3,211,130. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.16 trillion, a P/E ratio of 43.88, a P/E/G ratio of 1.51 and a beta of 0.51. The firm’s 50 day moving average is $1,065.45 and its 200 day moving average is $1,027.90.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm earned $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.74 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan lifted its price target on Eli Lilly to $1,400 and kept an Overweight rating, signaling confidence in further upside. Benzinga
• Positive Sentiment: Recent commentary continues to highlight Lilly’s leadership in GLP-1 obesity and diabetes drugs, which remain the main driver of revenue and investor enthusiasm.
• Positive Sentiment: Media coverage notes Lilly’s strong long-term growth case, with some analysts and market commentary pointing to sustained demand from its key drugs and pipeline expansion. Article
• Neutral Sentiment: Lilly also announced a new R&D collaboration with Abbisko and transferred China commercial rights for Verzenios to Innovent, reflecting ongoing portfolio and regional strategy adjustments. Yahoo Finance
• Negative Sentiment: Some recent coverage pointed to regulatory and drug-pricing policy concerns as a headwind, and the stock also slipped in the prior session, suggesting investors are still balancing optimism with policy risk. Yahoo Finance

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.